Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Anidulafungin (Eraxis, adults) - selected U.S. labeling
Product / population
Adult Candida infection treatment with intravenous anidulafungin. Pediatric doses are excluded.
Renal method
Qualitative renal guidance, including dialysis; no CrCl adjustment table.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Official
Anidulafungin (Eraxis, adults) - selected U.S. labeling
U.S. product labeling / DailyMed · Adult Candida infection treatment with intravenous anidulafungin. Pediatric doses are excluded.
Renal method: Qualitative renal guidance, including dialysis; no CrCl adjustment table. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
For candidemia/intra-abdominal abscess/peritonitis, give 200 mg IV on day 1, then 100 mg daily. The selected label describes at least 14 days after the last positive culture. Esophageal candidiasis instead uses 100 mg once then 50 mg daily, for at least 14 days and at least 7 days after symptom resolution.
Use the indication-specific regimen. Monitor hepatic abnormalities and infusion/hypersensitivity reactions; follow product-specific preparation and infusion instructions.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.